Evidence map›Paper›PMID 23579794›Full record

ArticleMemorias do Instituto Oswaldo Cruz2013

A population-based study of first and second-line drug-resistant tuberculosis in a high-burden area of the Mexico/United States border.

Pola Becerril-Montes, Salvador Said-Fernández, Julieta Luna-Herrera, Guillermo Caballero-Olín, José Antonio Enciso-Moreno, Herminia Guadalupe Martínez-Rodríguez, Gerardo Padilla-Rivas, Elsa Nancy-Garza-Treviño, Gloria María Molina-Salinas

Open access · diamondAbstract read
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Epidemiological surveillance of land borders in North and South America: a case study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pola Becerril-MontesDivisión de Biología Celular y Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México.
Salvador Said-Fernández
Julieta Luna-Herrera
Guillermo Caballero-Olín
José Antonio Enciso-Moreno
Herminia Guadalupe Martínez-Rodríguez
Gerardo Padilla-Rivas
Elsa Nancy-Garza-Treviño
Gloria María Molina-Salinas
Universidad Autónoma de Nuevo León · MXInstituto Politécnico Nacional · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The resistance of 139 Mycobacterium tuberculosis (MTB) isolates from the city of Monterrey, Northeast Mexico, to first and second-line anti-TB drugs was analysed. A total of 73 isolates were susceptible and 66 were resistant to anti-TB drugs. Monoresistance to streptomycin, isoniazid (INH) and ethambutol was observed in 29 cases. Resistance to INH was found in 52 cases and in 29 cases INH resistance was combined with resistance to two or three drugs. A total of 24 isolates were multidrug-resistant (MDR) resistant to at least INH and rifampicin and 11 MDR cases were resistant to five drugs. The proportion of MDR-TB among new TB cases in our target population was 0.72% (1/139 cases). The proportion of MDR-TB among previously treated cases was 25.18% (35/139 cases). The 13 polyresistant and 24 MDR isolates were assayed against the following seven second-line drugs: amikacin (AMK), kanamycin (KAN), capreomycin (CAP), clofazimine (CLF), ethionamide (ETH), ofloxacin (OFL) and cycloserine (CLS). Resistance to CLF, OFL or CLS was not observed. Resistance was detected to ETH (10.80%) and to AMK (2.70%), KAN (2.70%) and CAP (2.70%). One isolate of MDR with primary resistance was also resistant to three second-line drugs. Monterrey has a high prevalence of MDR-TB among previously treated cases and extensively drug-resistant-MTB strains may soon appear.

Indexed as

AdolescentAdultAntitubercular AgentsFemaleGeography, MedicalHumansMaleMexicoMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisRisk FactorsSocioeconomic FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultAntitubercular Agents

Identifiers

PMID23579794
PMCPMC3970668
OpenAlexW2137899176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.